{"id":"efavirenz-plus-lamivudine-zidovudine","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Dizziness and CNS effects (efavirenz)"},{"rate":"15-25","effect":"Rash"},{"rate":"10-20","effect":"Nausea"},{"rate":"10-15","effect":"Headache"},{"rate":"10-20","effect":"Lipodystrophy (zidovudine)"},{"rate":"5-15","effect":"Anemia (zidovudine)"},{"rate":"5-10","effect":"Peripheral neuropathy (lamivudine/zidovudine)"}]},"_chembl":{"chemblId":"CHEMBL223228","moleculeType":"Small molecule","molecularWeight":"315.68"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Efavirenz binds directly to HIV reverse transcriptase and blocks its catalytic activity. Lamivudine and zidovudine are nucleoside analogs that get incorporated into the growing viral DNA chain, causing chain termination and preventing viral replication. Together, these agents target reverse transcriptase through different mechanisms to suppress HIV viral load.","oneSentence":"This combination inhibits HIV reverse transcriptase through three complementary mechanisms: efavirenz as a non-nucleoside reverse transcriptase inhibitor and lamivudine/zidovudine as nucleoside reverse transcriptase inhibitors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:10:36.204Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT07080138","phase":"","title":"Research on the Psychological Status of Patients With HIV-1 Infection","status":"NOT_YET_RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-08-01","conditions":"HIV-1-infection, Anxiety Depression","enrollment":500},{"nctId":"NCT00476606","phase":"","title":"A Prospective Cohort of Children With HIV Infection","status":"COMPLETED","sponsor":"The HIV Netherlands Australia Thailand Research Collaboration","startDate":"2003-03","conditions":"HIV Infections","enrollment":500},{"nctId":"NCT03178084","phase":"PHASE3","title":"Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio","status":"COMPLETED","sponsor":"Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal","startDate":"2014-10-15","conditions":"HIV/AIDS","enrollment":721},{"nctId":"NCT05525156","phase":"PHASE2","title":"The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy","status":"SUSPENDED","sponsor":"Muhimbili University of Health and Allied Sciences","startDate":"2020-03-02","conditions":"Hiv, Cardiovascular Diseases","enrollment":454},{"nctId":"NCT00074581","phase":"PHASE3","title":"Preventing Sexual Transmission of HIV With Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-02","conditions":"HIV Infections","enrollment":3526},{"nctId":"NCT00039741","phase":"PHASE2, PHASE3","title":"Anti-HIV Drug Regimens and Treatment-Switching Guidelines in HIV Infected Children","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2002-08","conditions":"HIV Infections","enrollment":266},{"nctId":"NCT00001087","phase":"PHASE2","title":"The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00050895","phase":"PHASE3","title":"Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":775},{"nctId":"NCT00000885","phase":"PHASE2","title":"Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":440},{"nctId":"NCT03631732","phase":"PHASE3","title":"Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2018-08-28","conditions":"HIV-1 Infection","enrollment":496},{"nctId":"NCT02057796","phase":"PHASE4","title":"Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-09","conditions":"HIV-1 Infection","enrollment":1050},{"nctId":"NCT03284645","phase":"","title":"Viral and Antiretroviral Dynamics in HIV-1 Mother-to-Child Transmission Fluids","status":"COMPLETED","sponsor":"Obafemi Awolowo University","startDate":"2017-12-22","conditions":"Human Immunodeficiency Virus Infection","enrollment":194},{"nctId":"NCT01075152","phase":"PHASE4","title":"Cryptococcal Optimal ART Timing Trial","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2010-11","conditions":"Cryptococcal Meningitis, HIV Infections, AIDS","enrollment":177},{"nctId":"NCT01618305","phase":"PHASE4","title":"Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission","status":"COMPLETED","sponsor":"Westat","startDate":"2013-09-05","conditions":"HIV Infections","enrollment":408},{"nctId":"NCT00978068","phase":"PHASE3","title":"HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2009-09","conditions":"Malaria, HIV Infections","enrollment":176},{"nctId":"NCT00427297","phase":"PHASE3","title":"Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya","status":"TERMINATED","sponsor":"University of Washington","startDate":"2007-09","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT02499874","phase":"PHASE1","title":"SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women","status":"COMPLETED","sponsor":"St Stephens Aids Trust","startDate":"2015-08","conditions":"HIV","enrollment":26},{"nctId":"NCT01516970","phase":"PHASE3","title":"Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)","status":"COMPLETED","sponsor":"Janssen-Cilag G.m.b.H","startDate":"2011-11-25","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":312},{"nctId":"NCT02832778","phase":"PHASE1","title":"Pharmacokinetics of Efavirenz in the Presence of Rifampicin and Isoniazid","status":"UNKNOWN","sponsor":"St Stephens Aids Trust","startDate":"2016-11-21","conditions":"HIV","enrollment":35},{"nctId":"NCT01908660","phase":"","title":"Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions","status":"COMPLETED","sponsor":"Valme University Hospital","startDate":"2007-01","conditions":"Human Immunodeficiency Virus, Hepatitis B, Chronic, Hepatitis C, Chronic","enrollment":192},{"nctId":"NCT01192035","phase":"PHASE4","title":"PI or NNRTI as First-line Treatment of HIV in West Africa - the PIONA Trial","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2011-05","conditions":"HIV-1","enrollment":400},{"nctId":"NCT00192595","phase":"PHASE4","title":"Tenofovir in HIV/HBV Coinfection","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2004-01","conditions":"HIV Infection, Hepatitis B Coinfection","enrollment":36},{"nctId":"NCT01583439","phase":"NA","title":"The Mochudi Prevention Project ART Protocol","status":"TERMINATED","sponsor":"Harvard School of Public Health (HSPH)","startDate":"2012-09","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00031070","phase":"PHASE2","title":"Increasing HAART-Induced Immune Restoration With Cyclosporine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":40},{"nctId":"NCT01694017","phase":"PHASE4","title":"Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy","status":"COMPLETED","sponsor":"Tufts University","startDate":"2012-11","conditions":"HIV","enrollment":68},{"nctId":"NCT00120510","phase":"NA","title":"Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in Haiti","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-07","conditions":"HIV Infections, Tuberculosis","enrollment":816},{"nctId":"NCT01565889","phase":"PHASE1, PHASE2","title":"Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-03","conditions":"Hepatitis C, HIV","enrollment":52},{"nctId":"NCT00110305","phase":"PHASE2","title":"A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines","status":"COMPLETED","sponsor":"Tibotec Pharmaceuticals, Ireland","startDate":"2005-06","conditions":"Human Immunodeficiency Virus Type 1","enrollment":368},{"nctId":"NCT02028676","phase":"PHASE4","title":"Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa","status":"COMPLETED","sponsor":"Medical Research Council","startDate":"2007-03","conditions":"Human Immunodeficiency Virus","enrollment":1206},{"nctId":"NCT02002286","phase":"NA","title":"Safety and Efficacy Study of TwHF in HIV Patients With Poor Immune Responses","status":"COMPLETED","sponsor":"LI Taisheng","startDate":"2011-08","conditions":"HIV","enrollment":23},{"nctId":"NCT00234091","phase":"PHASE3","title":"When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-04","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00098293","phase":"PHASE3","title":"Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2004-11","conditions":"HIV-1","enrollment":916},{"nctId":"NCT00342355","phase":"PHASE4","title":"Antiretroviral Therapy for Advanced HIV Disease in South Africa","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"2004-01","conditions":"HIV","enrollment":1771},{"nctId":"NCT01817283","phase":"PHASE1, PHASE2","title":"Impact on T Cell Immune Activation and Inflammation of Triptolide Woldifii in HIV-infected Immunological Non-responders","status":"UNKNOWN","sponsor":"LI Taisheng","startDate":"2013-01","conditions":"HIV","enrollment":150},{"nctId":"NCT00666055","phase":"","title":"Sex, Aging and Antiretroviral Pharmacokinetics","status":"COMPLETED","sponsor":"Kristine Patterson, MD","startDate":"2008-03","conditions":"HIV Infections","enrollment":11},{"nctId":"NCT00000919","phase":"NA","title":"A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":900},{"nctId":"NCT00000903","phase":"PHASE3","title":"Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":444},{"nctId":"NCT00000918","phase":"PHASE2","title":"A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":300},{"nctId":"NCT00013897","phase":"PHASE3","title":"A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2001-02","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00001119","phase":"NA","title":"Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1999-10","conditions":"HIV Infections","enrollment":288},{"nctId":"NCT00028327","phase":"PHASE3","title":"Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":250},{"nctId":"NCT00100594","phase":"NA","title":"Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected People in Wenxi County, Shanxi Province, China","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2005-05","conditions":"HIV Infections","enrollment":100},{"nctId":"NCT01273142","phase":"","title":"Compare to the Safety of Efavirenz and Nevirapine in Treating HIV Positive Patients With Mild Baseline Liver Function Test Impairment, and/or Hepatitis B or Hepatitis C Co-infection","status":"UNKNOWN","sponsor":"Henan Provincial People's Hospital","startDate":"2011-01","conditions":"HIV Infections, Liver Toxicity, Hepatitis Co-infection","enrollment":100},{"nctId":"NCT00112047","phase":"PHASE3","title":"Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2003-07","conditions":"HIV Infections","enrollment":517},{"nctId":"NCT00966160","phase":"PHASE3","title":"CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes","status":"COMPLETED","sponsor":"University of Cologne","startDate":"1999-01","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":215},{"nctId":"NCT00158405","phase":"PHASE3","title":"Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2002-12","conditions":"HIV Infections","enrollment":840},{"nctId":"NCT00256828","phase":"PHASE4","title":"Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV","status":"COMPLETED","sponsor":"Clinical Trial Agency of HIV Study Group","startDate":"2004-06","conditions":"HIV Infections","enrollment":360},{"nctId":"NCT00127972","phase":"PHASE4","title":"2NN & CHARM Long-Term Follow-up Study","status":"COMPLETED","sponsor":"International Antiviral Therapy Evaluation Center","startDate":"2004-02","conditions":"HIV Infections","enrollment":763},{"nctId":"NCT00162643","phase":"PHASE4","title":"PI Vs. NNRTI Based Therapy for HIV Advanced Disease","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2004-12","conditions":"Acquired Immunodeficiency Syndrome","enrollment":300},{"nctId":"NCT00005000","phase":"PHASE4","title":"Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs","status":"UNKNOWN","sponsor":"Agouron Pharmaceuticals","startDate":"1999-12","conditions":"HIV Infections","enrollment":200},{"nctId":"NCT00005018","phase":"PHASE4","title":"Safety and Effectiveness of a Combination Anti-HIV Drug Treatment","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"1999-07","conditions":"HIV Infections","enrollment":150},{"nctId":"NCT00004852","phase":"PHASE2","title":"Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"1999-09","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT00011895","phase":"PHASE4","title":"Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs","status":"UNKNOWN","sponsor":"GlaxoSmithKline","startDate":"2001-02","conditions":"HIV Infections","enrollment":400},{"nctId":"NCT00004585","phase":"PHASE4","title":"A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults","status":"COMPLETED","sponsor":"Glaxo Wellcome","startDate":"1999-10","conditions":"HIV Infections","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Efavirenz plus Lamivudine/Zidovudine","genericName":"Efavirenz plus Lamivudine/Zidovudine","companyName":"University of Cologne","companyId":"university-of-cologne","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination inhibits HIV reverse transcriptase through three complementary mechanisms: efavirenz as a non-nucleoside reverse transcriptase inhibitor and lamivudine/zidovudine as nucleoside reverse transcriptase inhibitors. Used for HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}